Edition:
United States

Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

3,085JPY
5 Dec 2016
Change (% chg)

¥-70 (-2.22%)
Prev Close
¥3,155
Open
¥3,140
Day's High
¥3,160
Day's Low
¥3,075
Volume
1,402,200
Avg. Vol
1,161,882
52-wk High
¥4,685
52-wk Low
¥3,075

Latest Key Developments (Source: Significant Developments)

Chugai and Galderma announce global license agreement for Nemolizumab
Wednesday, 20 Jul 2016 07:30pm EDT 

Chugai Pharmaceutical Co Ltd <4519.T>: Chugai will continue to be responsible for product manufacturing and supply of Nemolizumab. . Under terms of agreement, Chugai will receive an upfront, milestone and royalty payments from Galderma. . Chugai and Galderma announce global license agreement for Nemolizumab (cim331), novel biologic for skin diseases . Chugai and Galderma announce global license agreement for Nemolizumab (cim331), novel biologic for skin diseases .Chugai will grant Galderma license for development and marketing of nemolizumab worldwide, exception of Japan and Taiwan.  Full Article

Chugai Pharmaceutical says concluded a license agreement with Roche
Wednesday, 1 Jun 2016 02:00am EDT 

Chugai Pharmaceutical Co Ltd: Announced that it concluded a license agreement with roche for "sa237" .Per the terms of the agreement, chugai will receive an upfront fee, milestone and royalty payments from roche..  Full Article

Six Japanese drugmakers will team up to discover new cancer, depression treatments - Nikkei
Wednesday, 25 May 2016 01:22pm EDT 

Nikkei: Astellas Pharma, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharmaceutical,Chugai Pharmaceutical will collaborate with 4 research institutions - Nikkei . The Six Drugmakers will work with research organizations providing cell, tissue samples to discover new pharmaceuticals - Nikkei . Around 3 billion Yen ($27.2 Million) will be put into drug-discovery efforts by fiscal 2019 - Nikkei .Group will create five teams looking into treatments for cancer, diabetic nephropathy and mental illnesses including depression - Nikkei.  Full Article

Chugai Pharmaceutical announces results of Japanese phase III study of Alecensa
Wednesday, 18 May 2016 09:25pm EDT 

Chugai Pharmaceutical Co Ltd : Announced results of Japanese phase III study of Alecensa in Alk fusion gene positive non-small cell lung cancer .PFS hazard ratio of Alecensa arm to Crizotinib arm was 0.34 and Alecensa demonstrated significantly prolonged PFS.  Full Article

Chugai Pharmaceutical wins Patent-Infringement lawsuit regarding OXAROL® Ointment
Friday, 25 Mar 2016 03:00am EDT 

Chugai Pharmaceutical Co Ltd:Wins a lawsuit filed by the company against companies which manufacturing and marketing their generic drugs in infringement of the process patent on "OXAROL® Ointment 25 μg/g", a Chugai's drug for treatment of keratosis including psoriasis vulgaris, on March 25.Says the grand panel judgment made by the Special Division of the Intellectual Property High Court was to reject the appeal by the generic companies, and by which, Chugai's claim was fully supported.  Full Article

Chiome Bioscience announces extension in agreement with Chugai Pharmaceutical
Wednesday, 16 Dec 2015 09:30pm EST 

Chiome Bioscience Inc:Announces extension of collaborative research agreement with Chugai Pharmaceutical.Expiry date was extended to Dec. 31, 2016.  Full Article

R&I affirms Chugai Pharmaceutical Co Ltd's rating at "AA-" and announces stable outlook
Friday, 16 Oct 2015 02:00am EDT 

Chugai Pharmaceutical Co Ltd:R&I affirms Chugai Pharmaceutical Co Ltd's rating at "AA-" and announces stable outlook.  Full Article

ASKA Pharmaceutical to acquire manufacturing and marketing approval right of antithyroid drugs from Chugai Pharmaceutical
Friday, 3 Apr 2015 02:00am EDT 

ASKA Pharmaceutical Co Ltd:Signed a contract on April 3 to acquire manufacturing and marketing approval right of two antithyroid drugs from Chugai Pharmaceutical on Oct. 1.  Full Article

Athersys Inc and Chugai Pharmaceutical Co Ltd enter license agreement and collaboration to develop MultiStem Cell Therapy
Monday, 2 Mar 2015 06:00am EST 

Athersys Inc and Chugai Pharmaceutical Co Ltd:Says a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan.Ischemic stroke represents a priority disease area in Japan, given the high healthcare burden of the condition and the expected increase in incidence associated with Japan's aging population.  Full Article

NanoCarrier signs joint research agreement with Chugai Pharmaceutical and to issue new shares
Tuesday, 24 Feb 2015 01:10am EST 

NanoCarrier Co Ltd:Signed a joint research agreement of siRNA drug with Chugai Pharmaceutical Co., Ltd.To issue 389,400 new shares to Chugai Pharmaceutical Co., Ltd. through private placement at 1,284 yen per share with amount of 499,989,600 yen.Payment date on March 12.Proceeds to be used as research and development expense of the joint research.  Full Article

BRIEF-Chugai, Berlin-Chemie Menarini set license agreement for PA799

* Roche's chugai and Berlin-Chemie Menarini Group announce global license agreement for an anti-cancer agent PA799 Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)